Analyst Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ocular Therapeutix and increased the price target to $27.00 from $24.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tazeen Ahmad has given his Buy rating due to a combination of factors tied to Axpaxli’s SOL-1 phase 3 data and its regulatory outlook. The Macula Society presentation addressed prior uncertainties, showing that Axpaxli meaningfully delays the need for rescue treatment and offers better fluid control, which in the analyst’s view strengthens the likelihood of approval and reduces risk in both the wet AMD and diabetic retinopathy programs.
Additional real‑world evidence suggests that patients similar to those in SOL-1 typically require many more injections to sustain the vision outcomes achieved with Axpaxli, underscoring its durability advantage and supporting higher value contributions in the model and a $27 price target. Safety concerns around floaters appear manageable based on detailed data and physician feedback, while the planned 505(b)(2) filing strategy could shorten the path to market, all of which underpin the reaffirmed Buy recommendation on OCUL.
In another report released yesterday, Clear Street also maintained a Buy rating on the stock with a $28.00 price target.
Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OCUL in relation to earlier this year.